Search

Your search keyword '"Grépin, Renaud"' showing total 144 results
Start Over Author "Grépin, Renaud"
144 results on '"Grépin, Renaud"'

1. Exploiting De Novo Serine Synthesis as a Metabolic Vulnerability to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma

Author

Teisseire, Manon, primary, Sahu, Umakant, additional, Parola, Julien, additional, Tsai, Meng-Chen, additional, Vial, Valérie, additional, Durivault, Jérôme, additional, Grépin, Renaud, additional, Cormerais, Yann, additional, Pagès, Gilles, additional, Ben-Sahra, Issam, additional, and Giuliano, Sandy, additional

Published
2024
Full Text
View/download PDF

3. NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft model

Author

Liu, Wang-Qing, Lepelletier, Yves, Montès, Matthieu, Borriello, Lucia, Jarray, Rafika, Grépin, Renaud, Leforban, Bertrand, Loukaci, Ali, Benhida, Rachid, Hermine, Olivier, Dufour, Sylvie, Pagès, Gilles, Garbay, Christiane, Raynaud, Françoise, Hadj-Slimane, Reda, and Demange, Luc

Published
2018
Full Text
View/download PDF

4. Supplementary Figure Legends from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Author

Dufies, Maeva, primary, Giuliano, Sandy, primary, Ambrosetti, Damien, primary, Claren, Audrey, primary, Ndiaye, Papa Diogop, primary, Mastri, Michalis, primary, Moghrabi, Walid, primary, Cooley, Lindsay S., primary, Ettaiche, Marc, primary, Chamorey, Emmanuel, primary, Parola, Julien, primary, Vial, Valerie, primary, Lupu-Plesu, Marilena, primary, Bernhard, Jean Christophe, primary, Ravaud, Alain, primary, Borchiellini, Delphine, primary, Ferrero, Jean-Marc, primary, Bikfalvi, Andréas, primary, Ebos, John M., primary, Khabar, Khalid Saad, primary, Grépin, Renaud, primary, and Pagès, Gilles, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table 4 from Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins

Author

Hitti, Edward, primary, Bakheet, Tala, primary, Al-Souhibani, Norah, primary, Moghrabi, Walid, primary, Al-Yahya, Suhad, primary, Al-Ghamdi, Maha, primary, Al-Saif, Maher, primary, Shoukri, Mohamed M., primary, Lánczky, András, primary, Grépin, Renaud, primary, Győrffy, Balázs, primary, Pagès, Gilles, primary, and Khabar, Khalid S.A., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Table 3- from Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins

Author

Hitti, Edward, primary, Bakheet, Tala, primary, Al-Souhibani, Norah, primary, Moghrabi, Walid, primary, Al-Yahya, Suhad, primary, Al-Ghamdi, Maha, primary, Al-Saif, Maher, primary, Shoukri, Mohamed M., primary, Lánczky, András, primary, Grépin, Renaud, primary, Győrffy, Balázs, primary, Pagès, Gilles, primary, and Khabar, Khalid S.A., primary

Published
2023
Full Text
View/download PDF

7. Supplemental Figure S3 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Author

Dufies, Maeva, primary, Giuliano, Sandy, primary, Ambrosetti, Damien, primary, Claren, Audrey, primary, Ndiaye, Papa Diogop, primary, Mastri, Michalis, primary, Moghrabi, Walid, primary, Cooley, Lindsay S., primary, Ettaiche, Marc, primary, Chamorey, Emmanuel, primary, Parola, Julien, primary, Vial, Valerie, primary, Lupu-Plesu, Marilena, primary, Bernhard, Jean Christophe, primary, Ravaud, Alain, primary, Borchiellini, Delphine, primary, Ferrero, Jean-Marc, primary, Bikfalvi, Andréas, primary, Ebos, John M., primary, Khabar, Khalid Saad, primary, Grépin, Renaud, primary, and Pagès, Gilles, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table 2 from Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins

Author

Hitti, Edward, primary, Bakheet, Tala, primary, Al-Souhibani, Norah, primary, Moghrabi, Walid, primary, Al-Yahya, Suhad, primary, Al-Ghamdi, Maha, primary, Al-Saif, Maher, primary, Shoukri, Mohamed M., primary, Lánczky, András, primary, Grépin, Renaud, primary, Győrffy, Balázs, primary, Pagès, Gilles, primary, and Khabar, Khalid S.A., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 1 from Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins

Author

Hitti, Edward, primary, Bakheet, Tala, primary, Al-Souhibani, Norah, primary, Moghrabi, Walid, primary, Al-Yahya, Suhad, primary, Al-Ghamdi, Maha, primary, Al-Saif, Maher, primary, Shoukri, Mohamed M., primary, Lánczky, András, primary, Grépin, Renaud, primary, Győrffy, Balázs, primary, Pagès, Gilles, primary, and Khabar, Khalid S.A., primary

Published
2023
Full Text
View/download PDF

10. Data from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Author

Dufies, Maeva, primary, Giuliano, Sandy, primary, Ambrosetti, Damien, primary, Claren, Audrey, primary, Ndiaye, Papa Diogop, primary, Mastri, Michalis, primary, Moghrabi, Walid, primary, Cooley, Lindsay S., primary, Ettaiche, Marc, primary, Chamorey, Emmanuel, primary, Parola, Julien, primary, Vial, Valerie, primary, Lupu-Plesu, Marilena, primary, Bernhard, Jean Christophe, primary, Ravaud, Alain, primary, Borchiellini, Delphine, primary, Ferrero, Jean-Marc, primary, Bikfalvi, Andréas, primary, Ebos, John M., primary, Khabar, Khalid Saad, primary, Grépin, Renaud, primary, and Pagès, Gilles, primary

Published
2023
Full Text
View/download PDF

11. Supplemental Table S1 from Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Author

Dufies, Maeva, primary, Giuliano, Sandy, primary, Ambrosetti, Damien, primary, Claren, Audrey, primary, Ndiaye, Papa Diogop, primary, Mastri, Michalis, primary, Moghrabi, Walid, primary, Cooley, Lindsay S., primary, Ettaiche, Marc, primary, Chamorey, Emmanuel, primary, Parola, Julien, primary, Vial, Valerie, primary, Lupu-Plesu, Marilena, primary, Bernhard, Jean Christophe, primary, Ravaud, Alain, primary, Borchiellini, Delphine, primary, Ferrero, Jean-Marc, primary, Bikfalvi, Andréas, primary, Ebos, John M., primary, Khabar, Khalid Saad, primary, Grépin, Renaud, primary, and Pagès, Gilles, primary

Published
2023
Full Text
View/download PDF

12. Supplemental Methods from Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins

Author

Hitti, Edward, primary, Bakheet, Tala, primary, Al-Souhibani, Norah, primary, Moghrabi, Walid, primary, Al-Yahya, Suhad, primary, Al-Ghamdi, Maha, primary, Al-Saif, Maher, primary, Shoukri, Mohamed M., primary, Lánczky, András, primary, Grépin, Renaud, primary, Győrffy, Balázs, primary, Pagès, Gilles, primary, and Khabar, Khalid S.A., primary

Published
2023
Full Text
View/download PDF

13. Data from Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins

Author

Hitti, Edward, primary, Bakheet, Tala, primary, Al-Souhibani, Norah, primary, Moghrabi, Walid, primary, Al-Yahya, Suhad, primary, Al-Ghamdi, Maha, primary, Al-Saif, Maher, primary, Shoukri, Mohamed M., primary, Lánczky, András, primary, Grépin, Renaud, primary, Győrffy, Balázs, primary, Pagès, Gilles, primary, and Khabar, Khalid S.A., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figures from Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins

Author

Hitti, Edward, primary, Bakheet, Tala, primary, Al-Souhibani, Norah, primary, Moghrabi, Walid, primary, Al-Yahya, Suhad, primary, Al-Ghamdi, Maha, primary, Al-Saif, Maher, primary, Shoukri, Mohamed M., primary, Lánczky, András, primary, Grépin, Renaud, primary, Győrffy, Balázs, primary, Pagès, Gilles, primary, and Khabar, Khalid S.A., primary

Published
2023
Full Text
View/download PDF

29. Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma

Author

Pagnuzzi-Boncompagni, Marina, primary, Picco, Vincent, additional, Vial, Valérie, additional, Planas-Bielsa, Victor, additional, Vandenberghe, Ashaina, additional, Daubon, Thomas, additional, Derieppe, Marie-Alix, additional, Montemagno, Christopher, additional, Durivault, Jérôme, additional, Grépin, Renaud, additional, Martial, Sonia, additional, Doyen, Jérôme, additional, Gavard, Julie, additional, and Pagès, Gilles, additional

Published
2021
Full Text
View/download PDF

30. Additional file 6 of Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Author

Dumond, Aurore, Brachet, Etienne, Durivault, Jérôme, Vial, Valérie, Puszko, Anna K., Lepelletier, Yves, Montemagno, Christopher, Pagnuzzi-Boncompagni, Marina, Hermine, Olivier, Garbay, Christiane, Lagarde, Nathalie, Montes, Matthieu, Demange, Luc, Grépin, Renaud, and Pagès, Gilles

Abstract

Additional file 6: Fig. S5. In-vivo effects of NRPa-308 on mice weight. The weight of nude mice xenografted with 786-O cells and treated with increasing doses of NRPa-308 was evaluated once a week.

Published
2021
Full Text
View/download PDF

31. Additional file 1 of Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Author

Dumond, Aurore, Brachet, Etienne, Durivault, Jérôme, Vial, Valérie, Puszko, Anna K., Lepelletier, Yves, Montemagno, Christopher, Pagnuzzi-Boncompagni, Marina, Hermine, Olivier, Garbay, Christiane, Lagarde, Nathalie, Montes, Matthieu, Demange, Luc, Grépin, Renaud, and Pagès, Gilles

Abstract

Additional file 1: Table S1. List of oligonucleotides used in qPCR experiments. Table S2. Recapitulative table of the expression of NRP1 and NRP2 in KO and knock-down cells. Table S3. Recapitulative table of the expression of VEGFA and VEGFC in KO and knock-down cells. Table S4. NRP1 and NRP2 binding site descriptors computed with DogSite Scorer (Nb: number, HBA: Hydrogen Bond Acceptor, HBD: Hydrogen Bond Donor, AA: amino acids).

Published
2021
Full Text
View/download PDF

32. Additional file 2 of Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Author

Dumond, Aurore, Brachet, Etienne, Durivault, Jérôme, Vial, Valérie, Puszko, Anna K., Lepelletier, Yves, Montemagno, Christopher, Pagnuzzi-Boncompagni, Marina, Hermine, Olivier, Garbay, Christiane, Lagarde, Nathalie, Montes, Matthieu, Demange, Luc, Grépin, Renaud, and Pagès, Gilles

Abstract

Additional file 2: Fig. S1. Study of down-regulation of NRPs by shRNA in 786-O cells. (A-B) Effects of the downregulation of NRP by shRNA on NRP1 and NRP2 mRNA expression measured by qPCR. (C) Effects on cell metabolic activity measured by MTT assays. (D) Down-regulation of NRPs decreased cell migration. Bevacizumab increased this effect for NRP1 down-regulation. (E) Down-regulation of NRPs had no effect on VEGFA and VEGFC production measured by ELISA. *p

Published
2021
Full Text
View/download PDF

33. Additional file 5 of Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Author

Dumond, Aurore, Brachet, Etienne, Durivault, Jérôme, Vial, Valérie, Puszko, Anna K., Lepelletier, Yves, Montemagno, Christopher, Pagnuzzi-Boncompagni, Marina, Hermine, Olivier, Garbay, Christiane, Lagarde, Nathalie, Montes, Matthieu, Demange, Luc, Grépin, Renaud, and Pagès, Gilles

Abstract

Additional file 5: Fig. S4. NRPs KO in RENCA tumor cells inhibited experimental RCC growth in immunodeficient mice. (A) Experimental tumors in nude mice were obtained after injection of 3 × 105 control (Ctrl, 10 mice) or NRPs KO RENCA cells (5 mice for each condition). One NRP1 KO clone (4.1 7) and one NRP2 KO clone (5.1 8) were injected. Tumor volume at the indicated times is presented. Each curve stands for an individual mouse.

Published
2021
Full Text
View/download PDF

34. Additional file 3 of Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Author

Dumond, Aurore, Brachet, Etienne, Durivault, Jérôme, Vial, Valérie, Puszko, Anna K., Lepelletier, Yves, Montemagno, Christopher, Pagnuzzi-Boncompagni, Marina, Hermine, Olivier, Garbay, Christiane, Lagarde, Nathalie, Montes, Matthieu, Demange, Luc, Grépin, Renaud, and Pagès, Gilles

Abstract

Additional file 3: Fig. S2. Effects of NRP1 or NRP2 gene invalidation in RENCA cells. (A) NRP1 and NRP2 protein levels were evaluated by flow cytometry in control (RENCA), in #NRP1 4.1.7 and #NRP2 5.1.8 clones. (B) Effects of NRPs KO on RENCA cell metabolic activity measured by MTT assays. (C) Effects of NRPs KO in RENCA cells on the VEGFA and VEGFC protein levels measured by ELISA. *p

Published
2021
Full Text
View/download PDF

36. Neuropilin 1 and Neuropilin 2 Gene Invalidation or Pharmacological Inhibition Reveals Their Relevance for the Treatment of Metastatic Renal Cell Carcinoma

Author

Dumond, Aurore, primary, Brachet, Etienne, additional, Durivault, Jérôme, additional, Vial, Valérie, additional, Puszko, Anna, additional, Lepelletier, Yves, additional, Montemagno, Christopher, additional, Pagnuzzi-Boncompagni, Marina, additional, Hermine, Olivier, additional, Garbay, Christiane, additional, Lagarde, Nathalie, additional, Montes, Matthieu, additional, Demange, Luc, additional, Grépin, Renaud, additional, and Pagès, Gilles, additional

Published
2020
Full Text
View/download PDF

37. The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor

Author

Grépin, Renaud, primary, Guyot, Mélanie, additional, Dumond, Aurore, additional, Durivault, Jérôme, additional, Ambrosetti, Damien, additional, Roussel, Jean-François, additional, Dupré, Florence, additional, Quintens, Hervé, additional, and Pagès, Gilles, additional

Published
2020
Full Text
View/download PDF

38. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies

Author

Guyot, Mélanie, Hilmi, Caroline, Ambrosetti, Damien, Merlano, Marco, Nigro, Cristiana Lo, Durivault, Jérôme, Grépin, Renaud, and Pagès, Gilles

Subjects
Vascular Endothelial Growth Factor A, renal cell carcinoma, Skin Neoplasms, Time Factors, Melanoma, Experimental, Mice, Nude, Angiogenesis Inhibitors, Transfection, Cancer Vaccines, angiogenesis, splicing, VEGF/VEGFxxxb, Cell Line, Tumor, Animals, Humans, Carcinoma, Renal Cell, Mice, Inbred BALB C, Neovascularization, Pathologic, Xenograft Model Antitumor Assays, Kidney Neoplasms, SRSF1, Bevacizumab, Gene Expression Regulation, Neoplastic, Mice, Inbred C57BL, Drug Resistance, Neoplasm, Female, RNA Interference, Research Paper, Signal Transduction
Abstract

Tumor growth relies on oxygen and blood supply depending on neo-vascularization. This process is mediated by the Vascular Endothelial Growth Factor (VEGF) in many tumors. This paradigm has led to the development of specific therapeutic approaches targeting VEGF or its receptors. Despite their promising effects, these strategies have not improved overall survival of patients suffering from different cancers compared to standard therapies. We hypothesized that the existence of anti-angiogenic forms of VEGF VEGFxxxb which are still present in many tumors limit the therapeutic effects of the anti-VEGF antibodies bevacizumab/Avastin (BVZ). To test this hypothesis, we generated renal cell carcinoma cells (RCC) expressing VEGF165b. The incidence of tumors xenografts generated in nude mice and their growth were inferior to those obtained with control cells. Whereas BVZ had no effect on control tumors, it slowed-down the growth of tumor generated with VEGF165b expressing cells. A prophylactic immunization against the domain discriminating VEGF from VEGFxxxb isoforms inhibited the growth of tumor generated with two different syngenic tumor cell lines (melanoma (B16 cells) and RCC (RENCA cells)). Purified immunoglobulins from immunized mice also slowed-down tumor growth of human RCC xenografts in nude mice, producing a potent effect compared to BVZ in this model. Furthermore, down-regulating the serine-arginine-rich splicing factor 1 (SRSF1) or masking SRSF1 binding sites by 2'O-Methyl RNA resulted in the increase of the VEGFxxxb/VEGF ratio. Therefore, a vaccine approach, specific antibodies against pro-angiogenic forms of VEGF, or increasing the VEGFxxxb/VEGF ratio may represent new prophylactic or pro-active anti-cancer strategies.

Published
2016

39. New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments

Author

Dufies, Maeva, Grytsai, Oleksandr, Ronco, Cyril, Camara, Oumar, Ambrosetti, Damien, Hagege, Anaïs, Parola, Julien, Mateo, Lou, Ayrault, Marion, Giuliano, Sandy, Grépin, Renaud, Lagarde, Nathalie, Montes, Matthieu, Auberger, Patrick, Demange, Luc, Benhida, Rachid, Pagès, Gilles, Centre Scientifique de Monaco (CSM), Institut de Chimie de Nice (ICN), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Hôpital Pasteur [Nice] (CHU), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Cibles Thérapeutiques et conception de médicaments (CiTCoM - UMR 8038), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Laboratoire Génomique, bioinformatique et chimie moléculaire (GBCM), Conservatoire National des Arts et Métiers [CNAM] (CNAM), Centre méditerranéen de médecine moléculaire (C3M), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Puybonnieux, Aurélie, Université Nice Sophia Antipolis (1965 - 2019) (UNS), Université Paris Descartes - Paris 5 (UPD5)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), and HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)

Subjects
Cell Survival, Antineoplastic Agents, Apoptosis, [SDV.CAN]Life Sciences [q-bio]/Cancer, Review, urologic and male genital diseases, Receptors, Interleukin-8B, Receptors, Interleukin-8A, Inhibitory Concentration 50, Mice, angiogenesis, Head and Neck Squamous Cell Carcinoma, [SDV.CAN] Life Sciences [q-bio]/Cancer, Cell Movement, Cell Line, Tumor, Animals, Humans, ELR+CXCL cytokines, CXCR1/2 inhibitor, neoplasms, Cell Proliferation, Clear cell Renal Cell Carcinoma, Prognosis, ELR + CXCL cytokines, Xenograft Model Antitumor Assays, Kidney Neoplasms, female genital diseases and pregnancy complications, Molecular Docking Simulation, stomatognathic diseases, Head and Neck Neoplasms, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Signal Transduction
Abstract

International audience; Clear cell Renal Cell (RCC) and Head and Neck Squamous Cell Carcinomas (HNSCC) are characterized by a pro-angiogenic/pro-inflammatory context. Despite conventional or targeted therapies, metastatic RCC and HNSCC remain incurable. Alternative treatments to reference therapies (sunitinib, a multi tyrosine kinase inhibitor for RCC or cisplatin for HNSCC) are urgently needed on relapse. Here, we described the relevance of targeting the ELR+CXCL cytokines receptors, CXCR1/2, for the treatment of these two cancer types.Methods: The relevance to patient treatment was evaluated by correlating the ELR+CXCL/CXCR1/2 levels to survival using online available data. We report herein the synthesis of new pharmacological inhibitors of CXCR1/2 with anti-proliferation/survival activity. The latter was evaluated with the XTT assay with leukemic, breast, RCC and HNSCC cell lines. Their relevance as an alternative treatment was tested on sunitinib- and cisplatin- resistant cells. The most efficient compound was then tested in a mouse model of RCC and HNSCC.Results: RCC and HNSCC expressed the highest amounts of CXCR1/2 of all cancers. High levels of ELR+CXCL cytokines (CXCL1, 2, 3, 5, 6, 7, 8) correlated to shorter survival. Among the 33 synthesized and tested molecules, compound C29 reduced ELR+CXCL/CXCR1/2-dependent proliferation and migration of endothelial cells. C29 exerted an anti-proliferation/survival activity on a panel of cancer cells including naive and resistant RCC and HNSCC cells. C29 reduced the growth of experimental RCC and HNSCC tumors by decreasing tumor cell proliferation, angiogenesis and ELR+/CXCL-mediated inflammation.Conclusion: Our study highlights the relevance of new CXCR1/2 inhibitors for the treatment of RCC or HNSCC as first-line treatment or at relapse on reference therapies.

Published
2019

40. Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma

Author

Dufies, Maeva, Nollet, Marie, Ambrosetti, Damien, Traboulsi, Wael, Viotti, Julien, Borchiellini, Delphine, Grépin, Renaud, Parola, Julien, Giuliano, Sandy, Helley-Russick, Dominique, Bensalah, Karim, Ravaud, Alain, Bernhard, Jean-Christophe, Schiappa, Renaud, Bardin, Nathalie, Dignat-George, Francoise, Rioux-Leclercq, Nathalie, Oudard, Stéphane, Négrier, Sylvie, Ferrero, Jean-Marc, Chamorey, Emmanuel, Blot-Chabaud, Marcel, Pagès, Gilles, Centre Scientifique de Monaco (CSM), Musee oceanographique de Monaco, Centre recherche en CardioVasculaire et Nutrition (C2VN), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Côte d'Azur (UCA), CNRS UMR7284, INSERM U1081, Institute for Research on Cancer and Aging, Nice (IRCAN), Centre Antoine Lacassagne, Centre Antoine Lacassagne, CRLCC Antoine Lacassagne, Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA), Assistance Publique-Hôpitaux de Paris, Hopital Europeen Georges Pompidou, F-75015 Paris, France, CHU Pontchaillou [Rennes], Département d'Oncologie [CHU Bordeaux] (Cancérologie/Oncologie/Digestive), GH Sud Haut-Lévêque [CHU Hôpitaux de Bordeaux] (Centre médico chirurgical Magellan)-Hôpital Saint-André [CHU de Bordeaux], service d'urologie [CHU Bordeaux], CHU Bordeaux [Bordeaux], Université de Bordeaux (UB), Service d'anatomie et cytologie pathologiques [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Léon Bérard [Lyon], French association for cancer research, Fondation de France, French National Institute for Cancer Research, Inserm, AMU, MSD Avenir, FX Mora Foundation, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes], Université Nice Sophia Antipolis (1965 - 2019) (UNS), Hôpital Haut-Lévêque - CHU de Bordeaux (Centre médico chirurgical Magellan)-Hôpital Saint-André [CHU de Bordeaux], and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Male, sCD146, clear cell renal cell carcinoma, sunitinib, predictive marker, plasma, pronostic, [SDV]Life Sciences [q-bio], carcinome, Antineoplastic Agents, CD146 Antigen, gène marqueur, développement in vitro, urologic and male genital diseases, Disease-Free Survival, cellule rénale, tumeur, Biomarkers, Tumor, Urology and Nephrology, Humans, Prospective Studies, Carcinoma, Renal Cell, Urologie et Néphrologie, Retrospective Studies, gène tumoral, Middle Aged, Prognosis, Kidney Neoplasms, Bevacizumab, Female, Neoplasm Recurrence, Local, Research Paper
Abstract

International audience; The objective of the study was to use CD146 mRNA to predict the evolution of patients with non-metastatic clear cell renal cell carcinoma (M0 ccRCC) towards metastatic disease, and to use soluble CD146 (sCD146) to anticipate relapses on reference treatments by sunitinib or bevacizumab in patients with metastatic ccRCC (M1). Methods: A retrospective cohort of M0 patients was used to determine the prognostic role of intra-tumor CD146 mRNA. Prospective multi-center trials were used to define plasmatic sCD146 as a predictive marker of sunitinib or bevacizumab efficacy for M1 patients. Results: High tumor levels of CD146 mRNA were linked to shorter disease-free survival (DFS) and overall survival (OS). ccRCC patients from prospective cohorts with plasmatic sCD146 variation

Published
2018

41. VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness

Author

Ndiaye, Papa Diogop, primary, Dufies, Maeva, additional, Giuliano, Sandy, additional, Douguet, Laetitia, additional, Grépin, Renaud, additional, Durivault, Jérôme, additional, Lenormand, Philippe, additional, Glisse, Natacha, additional, Mintcheva, Janita, additional, Vouret-Craviari, Valérie, additional, Mograbi, Baharia, additional, Wurmser, Maud, additional, Ambrosetti, Damien, additional, Rioux-Leclercq, Nathalie, additional, Maire, Pascal, additional, and Pagès, Gilles, additional

Published
2019
Full Text
View/download PDF

42. CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

Author

Dufies, Maeva, primary, Giuliano, Sandy, additional, Viotti, Julien, additional, Borchiellini, Delphine, additional, Cooley, Linsay S, additional, Ambrosetti, Damien, additional, Guyot, Mélanie, additional, Ndiaye, Papa Diogop, additional, Parola, Julien, additional, Claren, Audrey, additional, Schiappa, Renaud, additional, Gal, Jocelyn, additional, Frangeul, Antoine, additional, Jacquel, Arnaud, additional, Cassuto, Ophélie, additional, Grépin, Renaud, additional, Auberger, Patrick, additional, Bikfalvi, Andréas, additional, Milano, Gérard, additional, Escudier, Bernard, additional, Rioux-Leclercq, Nathalie, additional, Porta, Camillo, additional, Negrier, Sylvie, additional, Chamorey, Emmanuel, additional, Ferrero, Jean-Marc, additional, and Pagès, Gilles, additional

Published
2017
Full Text
View/download PDF

43. Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas

Author

Dufies, Maeva, primary, Giuliano, Sandy, additional, Ambrosetti, Damien, additional, Claren, Audrey, additional, Ndiaye, Papa Diogop, additional, Mastri, Michalis, additional, Moghrabi, Walid, additional, Cooley, Lindsay S., additional, Ettaiche, Marc, additional, Chamorey, Emmanuel, additional, Parola, Julien, additional, Vial, Valerie, additional, Lupu-Plesu, Marilena, additional, Bernhard, Jean Christophe, additional, Ravaud, Alain, additional, Borchiellini, Delphine, additional, Ferrero, Jean-Marc, additional, Bikfalvi, Andréas, additional, Ebos, John M., additional, Khabar, Khalid Saad, additional, Grépin, Renaud, additional, and Pagès, Gilles, additional

Published
2017
Full Text
View/download PDF

44. The ELR+CXCL chemokines and their receptors CXCR1/CXCR2

Author

Giuliano, Sandy, Guyot, Mélanie, Grépin, Renaud, and Pagès, Gilles

Subjects
angiogenesis, renal cell carcinoma, ELR+CXCL, CXCR2, CXCR1, inflammation, CXCL7, Author's View
Abstract

The long-term efficacy of anti-angiogenesis drugs targeting vascular endothelial growth factor (VEGF) and VEGF receptors in the treatment of renal cell carcinoma (RCC) has been lacking. We have shown that the ELR+CXCL cytokines and their (C-X-C) chemokine receptors, namely CXCR1 and CXCR2, stimulate cancer cell proliferation, tumor inflammation, and angiogenesis. Hence, this essential molecular nexus regulating cancer growth represents a key therapeutic target.

Published
2014

45. Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins

Author

Hitti, Edward, primary, Bakheet, Tala, additional, Al-Souhibani, Norah, additional, Moghrabi, Walid, additional, Al-Yahya, Suhad, additional, Al-Ghamdi, Maha, additional, Al-Saif, Maher, additional, Shoukri, Mohamed M., additional, Lánczky, András, additional, Grépin, Renaud, additional, Győrffy, Balázs, additional, Pagès, Gilles, additional, and Khabar, Khalid S.A., additional

Published
2016
Full Text
View/download PDF

46. Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression

Author

Zakraoui, Ons, primary, Marcinkiewicz, Cezary, additional, Aloui, Zohra, additional, Othman, Houcemeddine, additional, Grépin, Renaud, additional, Haoues, Meriam, additional, Essafi, Makram, additional, Srairi-Abid, Najet, additional, Gasmi, Ammar, additional, Karoui, Habib, additional, Pagès, Gilles, additional, and Essafi-Benkhadir, Khadija, additional

Published
2016
Full Text
View/download PDF

47. Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux

Author

Giuliano, Sandy, primary, Cormerais, Yann, additional, Dufies, Maeva, additional, Grépin, Renaud, additional, Colosetti, Pascal, additional, Belaid, Amine, additional, Parola, Julien, additional, Martin, Anthony, additional, Lacas-Gervais, Sandra, additional, Mazure, Nathalie M, additional, Benhida, Rachid, additional, Auberger, Patrick, additional, Mograbi, Baharia, additional, and Pagès, Gilles, additional

Published
2015
Full Text
View/download PDF

48. [The Vascular Endothelial Growth Factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?]

Author

Grépin, Renaud, Pagès, Gilles, Institut de signalisation, biologie du développement et cancer (ISBDC), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)

Subjects
Oncogene Proteins, Vascular Endothelial Growth Factor A, Clinical Trials as Topic, Neovascularization, Pathologic, Antibodies, Monoclonal, Angiogenesis Inhibitors, Antineoplastic Agents, Protein-Tyrosine Kinases, Antibodies, Monoclonal, Humanized, Neoplasm Proteins, Bevacizumab, Drug Delivery Systems, Receptors, Vascular Endothelial Growth Factor, Gene Expression Regulation, Neoplasms, Humans, Intercellular Signaling Peptides and Proteins, Protein Isoforms, Neoplasm Invasiveness, RNA, Messenger, RNA, Neoplasm, Promoter Regions, Genetic, 3' Untranslated Regions, [SDV.BDD]Life Sciences [q-bio]/Development Biology, Signal Transduction
Abstract

International audience; VEGF represents a model of gene expression regulation. RAS/RAF/MEK/ERK and PI3 Kinase pathways, activated in response to growth factors stimulation or by oncogenes, contribute to its expression by activating transcription factors or inactivating proteins implicated in degradation of its mRNA. These factors (Sp1/Sp3, HIF-1 and TTP) constitute molecular markers of tumor aggressiveness. VEGF is overexpressed in solid or hematologic tumors. Thus, numerous compounds regulating angiogenesis by targeting VEGF have been developed. However, their effects are not as spectacular as expected. The existence of anti-angiogenic isoforms of VEGF could be a cause of their less potent activity. These different points are discussed in this review article. Le VEGF constitue un modèle de régulation d'expression génique. Les voies de signalisation RAS/RAF/MEK ERK et PI3 Kinase induites par des facteurs de croissance ou des oncogènes contribuent à son expression notamment en activant des facteurs de transcription requis pour la transcription de son gène mais aussi en inactivant des protéines impliquées dans la dégradation de son ARNm. Ces facteurs (Sp1/Sp3, HIF-1 et TTP) constituent des marqueurs moléculaires de l'agressivité tumorale. Le VEGF est surexprimé dans un grand nombre de tumeurs solides et hématologiques. Ainsi de nombreux composés régulant l'angiogenèse en ciblant le VEGF et/ou ses récepteurs ont vu le jour. Cependant leur effet n'est pas aussi spectaculaire que prévu. La présence de formes anti-angiogéniques du VEGF pourrait en être partiellement la cause. Ces différents points sont discutés dans cet article de revue.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results